Citigroup Lowers Health Catalyst (NASDAQ:HCAT) Price Target to $1.75

Health Catalyst (NASDAQ:HCAT) had its target price lowered by equities researchers at Citigroup from $2.75 to $1.75 in a note issued to investors on Friday,Benzinga reports. The brokerage presently has a “neutral” rating on the stock. Citigroup’s price target would indicate a potential upside of 32.58% from the company’s current price.

A number of other research analysts have also commented on the company. Stifel Nicolaus cut their target price on Health Catalyst from $3.75 to $2.00 and set a “hold” rating for the company in a research note on Friday. Canaccord Genuity Group lowered their price target on shares of Health Catalyst from $5.00 to $2.00 and set a “buy” rating on the stock in a report on Friday. Stephens dropped their price objective on shares of Health Catalyst from $3.50 to $2.00 and set an “equal weight” rating for the company in a research note on Friday. Raymond James Financial set a $3.00 price objective on shares of Health Catalyst in a report on Friday. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Health Catalyst in a research note on Monday, December 29th. Five research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $3.16.

Health Catalyst Stock Performance

Health Catalyst stock traded down $0.47 during trading hours on Friday, hitting $1.32. The stock had a trading volume of 2,546,352 shares, compared to its average volume of 844,422. The company has a 50-day moving average of $2.07 and a two-hundred day moving average of $2.58. The company has a quick ratio of 1.88, a current ratio of 1.88 and a debt-to-equity ratio of 0.46. Health Catalyst has a fifty-two week low of $1.20 and a fifty-two week high of $5.06. The company has a market cap of $93.36 million, a PE ratio of -0.83 and a beta of 1.76.

Institutional Investors Weigh In On Health Catalyst

Institutional investors and hedge funds have recently made changes to their positions in the company. First Light Asset Management LLC increased its position in shares of Health Catalyst by 9.9% during the 3rd quarter. First Light Asset Management LLC now owns 13,436,220 shares of the company’s stock worth $38,293,000 after purchasing an additional 1,206,039 shares in the last quarter. Vanguard Group Inc. boosted its position in Health Catalyst by 2.9% in the third quarter. Vanguard Group Inc. now owns 4,295,691 shares of the company’s stock valued at $12,243,000 after buying an additional 119,117 shares in the last quarter. Whetstone Capital Advisors LLC grew its stake in Health Catalyst by 0.5% during the fourth quarter. Whetstone Capital Advisors LLC now owns 3,750,377 shares of the company’s stock worth $8,963,000 after buying an additional 19,027 shares during the last quarter. Nepsis Inc. grew its stake in Health Catalyst by 26.6% during the fourth quarter. Nepsis Inc. now owns 1,915,794 shares of the company’s stock worth $4,579,000 after buying an additional 402,762 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Health Catalyst by 11.4% during the second quarter. Geode Capital Management LLC now owns 1,662,455 shares of the company’s stock worth $6,269,000 after buying an additional 169,580 shares in the last quarter. Institutional investors and hedge funds own 85.00% of the company’s stock.

Key Stories Impacting Health Catalyst

Here are the key news stories impacting Health Catalyst this week:

• Positive Sentiment: Revenue and full-year profitability metrics show some underlying strength — Q4 revenue came in roughly $74.7M (slightly above consensus) and FY2025 revenue totaled $311.1M with Adjusted EBITDA of $41.4M, which investors could view as signs of durable demand and improving margin progress. GlobeNewswire – Press Release
• Positive Sentiment: Some technical/analyst commentary suggests the stock may be finding a bottom and could attract value buyers if earnings-revision momentum continues. Zacks – Technical/Buy Thesis
• Neutral Sentiment: Earnings call transcript and company materials are available for deeper read-through if you want management’s commentary on growth, margins and 2026 priorities. Seeking Alpha – Call Transcript
• Neutral Sentiment: Company published its Q4 and full-year release and conference call materials (press release and transcript available). These provide the official detail behind revenue, EBITDA and management commentary. Press Release / Report PDF
• Negative Sentiment: Q4 EPS missed expectations — reported $0.08 vs Zacks/consensus near $0.09–$0.10, which disappointed traders focused on near-term profitability. Zacks – EPS Miss
• Negative Sentiment: Q1 2026 revenue guidance of $68.0M–$70.0M came in well below the prior consensus (~$74.1M), signaling slower near-term revenue growth and prompting investor concern. MarketBeat – Guidance Details
• Negative Sentiment: Analysts trimmed targets and ratings: Stephens cut its PT from $3.50 to $2.00 (equal weight) and Stifel lowered its PT from $3.75 to $2.00 (hold), which reduces buy-side conviction and can pressure the stock despite the still-stated upside to $2.00. Benzinga – PT Cuts TickerReport – Stifel Note
• Negative Sentiment: Underlying profitability metrics remain stretched: the company reported a negative net margin (~-34%) and negative ROE, highlighting continued path-to-profitability risks for some investors. MarketBeat – Financial Metrics

About Health Catalyst

Health Catalyst (NASDAQ: HCAT) is a healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has since focused on delivering a unified data platform that helps healthcare organizations aggregate and analyze clinical, financial and operational information.

The core of Health Catalyst’s offering is the Data Operating System (DOS), a modular data management platform that integrates disparate data sources—from electronic health records to claims and patient-generated data—into a single analytics environment.